Progress in Pediatric Cardiology
Volume 23, Issue 1 , Pages 61-66 , September 2007

Novel medical therapies for pediatric heart failure

References 

  1. Rosenthal D, Chrisant MR, Edens E, et al. International society for heart and lung transplantation: practice guidelines for management of heart failure in children. J Heart Lung Transplant. 2004;23(12):1313–1333
  2. Jefferies JL, Eidem BW, Belmont JW, et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation. 2005;112(18):2799–2804
  3. Caspi J, Coles JG, Benson LN, et al. Age-related response to epinephrine-induced myocardial stress. A functional and ultrastructural study. Circulation. 1991;84(5 Suppl):III394–III399
  4. Caspi J, Coles JG, Benson LN, et al. Effects of high plasma epinephrine and Ca2+ concentrations on neonatal myocardial function after ischemia. J Thorac Cardiovasc Surg. 1993;105(1):59–67
  5. Edes I, Kiss E, Kitada Y, et al. Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res. 1995;77(1):107–113
  6. Kopustinskiene DM, Pollesello P, Saris NE. Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol. 2001;428(3):311–314
  7. Adamopoulos S, Parissis JT, Iliodromitis EK, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol. 2006;98(1):102–106
  8. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360(9328):196–202
  9. Nguyen HD, McKeown B. Levosimendan for post-partum cardiomyopathy. Crit Care Resusc. 2005;7(2):107–110
  10. Parissis JT, Paraskevaidis I, Bistola V, et al. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol. 2006;98(11):1489–1492
  11. Namachivayam P, Crossland DS, Butt WW, Shekerdemian LS. Early experience with levosimendan in children with ventricular dysfunction. Pediatr Crit Care Med. 2006;7(5):445–448
  12. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343(4):246–253
  13. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287(12):1531–1540
  14. Yamamoto K, Burnett JC, Redfield MM. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol. 1997;273(5 Pt 2):H2406–H2414
  15. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991;84(4):1581–1588
  16. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4(1):37–44
  17. Feingold B, Law YM. Nesiritide use in pediatric patients with congestive heart failure. J Heart Lung Transplant. 2004;23(12):1455–1459
  18. Marshall J, Berkenbosch JW, Russo P, Tobias JD. Preliminary experience with nesiritide in the pediatric population. J Intensive Care Med. 2004;19(3):164–170
  19. Moffett BS, Jefferies JL, Price JF, et al. Administration of a large nesiritide bolus dose in a pediatric patient: case report and review of nesiritide use in pediatrics. Pharmacotherapy. 2006;26(2):277–280
  20. Moffett BS, Jefferies JL, Rossano J, Towbin JA. Nesiritide therapy in a term neonate with renal disease. Pharmacotherapy. 2006;26(2):281–284
  21. Jefferies JL, Denfield SW, Price JF, et al. A prospective evaluation of nesiritide in the treatment of pediatric heart failure. Pediatr Cardiol. 2006;27(4):402–407
  22. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111(12):1487–1491
  23. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med. 2004;164(13):1427–1436
  24. Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis. 2005;178(2):359–363
  25. Strey CH, Young JM, Molyneux SL, et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis. 2005;179(1):201–206
  26. Urbich C, Dimmeler S. Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney Int. 2005;67(5):1672–1676
  27. Bohm M, Hjalmarson A, Kjekshus J, Laufs U, McMurray J, van Veldhuisen DJ. Heart failure and statins—why do we need a clinical trial?. Z Kardiol. 2005;94(4):223–230
  28. Rundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol. 2004;61(6):889–892
  29. Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet. 2004;363(9412):892–894
  30. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109(23 Suppl 1):III50–III57
  31. Wojnicz R, Wilczek K, Nowalany-Kozielska E, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol. 2006;97(6):899–904
  32. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47(2):332–337
  33. Sola S, Mir MQ, Rajagopalan S, Helmy T, Tandon N, Khan BV. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail. 2005;11(8):607–612
  34. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006;296(17):2105–2111
  35. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006;8(1):105–110
  36. Gazi IF, Liberopoulos EN, Athyros VG, Elisaf M, Mikhailidis DP. Statins and solid organ transplantation. Curr Pharm Des. 2006;12(36):4771–4783
  37. Arambepola C, Farmer AJ, Perera R, Neil HA. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. Atherosclerosis in press. [Electronic publication ahead of print, November 9, 2006], doi:10.1016/j.atherosclerosis.2006.09.030.
  38. Belay B, Belamarich PF, Tom-Revzon C. The use of statins in pediatrics: knowledge base, limitations, and future directions. Pediatrics. 2007;119(2):370–380
  39. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345(20):1435–1443
  40. Blume ED, Naftel DC, Bastardi HJ, Duncan BW, Kirklin JK, Webber SA. Outcomes of children bridged to heart transplantation with ventricular assist devices: a multi-institutional study. Circulation. 2006;113(19):2313–2319
  41. Moss AJ. MADIT-I and MADIT-II. J Cardiovasc Electrophysiol. 2003;14(9 Suppl):S96–S98
  42. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–237
  43. Schaechter A, Kadish AH. DEFibrillators in non-ischemic cardiomyopathy treatment evaluation (DEFINITE). Card Electrophysiol Rev. 2003;7(4):457–462
  44. Abraham WT. Cardiac resynchronization therapy. Prog Cardiovasc Dis. 2006;48(4):232–238
  45. Nelson GS, Curry CW, Wyman BT, et al. Predictors of systolic augmentation from left ventricular preexcitation in patients with dilated cardiomyopathy and intraventricular conduction delay. Circulation. 2000;101(23):2703–2709
  46. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–1549
  47. Sutton MG, Plappert T, Hilpisch KE, Abraham WT, Hayes DL, Chinchoy E. Sustained reverse left ventricular structural remodeling with cardiac resynchronization at one year is a function of etiology: quantitative Doppler echocardiographic evidence from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). Circulation. 2006;113(2):266–272
  48. Yu CM, Wing-Hong Fung J, Zhang Q, Sanderson JE. Understanding nonresponders of cardiac resynchronization therapy—current and future perspectives. J Cardiovasc Electrophysiol. 2005;16(10):1117–1124
  49. McMurray JJ. What are the clinical consequences of anemia in patients with chronic heart failure?. J Card Fail. 2004;10(1 Suppl):S10–S12
  50. Bolger AP, Bartlett FR, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48(6):1225–1227
  51. Streeter RP, Mancini D. Treatment of anemia in the patient with heart failure. Curr Treat Options Cardiovasc Med. 2005;7(4):327–332
  52. Neuberg GW, Miller AB, O'Connor CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144(1):31–38
  53. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43(1):61–67
  54. Hoffman TM, Wernovsky G, Atz AM, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation. 2003;107(7):996–1002
  55. Wessel DL. Testing new drugs for heart failure in children. Pediatr Crit Care Med. 2006;7(5):493–494

PII: S1058-9813(07)00005-7

doi: 10.1016/j.ppedcard.2007.05.004

Progress in Pediatric Cardiology
Volume 23, Issue 1 , Pages 61-66 , September 2007

Article Tools

* Image Usage & Resolution